Zanidatamab
Multispecific antibody
Evidence outlook
Approved: Biliary Tract Cancer [accelerated] (label: previously treated, unresectable or metastatic HER2-positive (IHC 3+) biliary tract cancer), Gastric Cancer
Accelerated approval is granted on surrogate endpoints; confirmatory clinical benefit is being verified in ongoing trials. Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
track record: Weak signalSingle-arm, accepted for approval (FDA label)
Also in development:Non-Small Cell Lung Cancer · Phase 2HER2-Positive Breast Cancer · Phase 3
Also approved (3)
- Gastroesophageal Adenocarcinoma (GEA) • ZIIHERA, in combination with fluoropyrimidine- and platinum-containing chemotherapy and tislelizumab-jsgr, is indicated for the first-line treatment of adult patients with HER2-positive (IHC 3+ or IHC 2+/ISH+) unresectable locally advanced or metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma, as detected by an FDA-authorized test [see Dosage and Administration ( 2.1 )] . • ZIIHERA, in combination with fluoropyrimidine- and platinum-containing chemotherapy, is indicated for the first-line treatment of adult patients with HER2-pos
- Ziihera as monotherapy is indicated for the treatment of adults with unresectable locally advanced or metastatic HER2-positive (IHC3+) biliary tract cancer (BTC) previously treated with at least one prior line of systemic therapy (for biomarker-based patient selection, see section 4.2).
- Conditional approval: previously treated, unresectable or metastatic HER2-positive (HER2+) biliary tract cancer
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
HERIZON-BTC-01 NCT04466891 · Biliary Tract Cancer This was a single-arm, open-label study of 87 participants, so responses cannot be directly compared with placebo or another treatment. The objective-response primary endpoint was met in the reported analysis, but the lack of randomization, blinding, and a comparator limits the strength of the evidence. Registry: NCT04466891 | 2 | Confirmed Objective Response Rate (ORR) 2023-07-28 | Confirmed ORR 41.3% (95% CI 30.4-52.8); median duration of response 12.9 months (Lancet Oncol 2023) | Weak signal | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.
Phase 3 (6)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 2 (19)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 1/2 (6)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 1 (2)
What this study did
What this study did
Appears in other studies (1)
Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.
Phase 1/2 (1)
What this study did
Competitive landscape
Other HER2 drugs
margetuximab, Trastuzumab Deruxtecan, Tucatinib, Disitamab Vedotin, Trastuzumab brengitecan and 11 more. Compare all 17 HER2 drugs
This mechanism is crowded: 16 other tracked programmes target it, none of them ahead of this one.
This drug's own stage for Biliary Tract Cancer: Approved. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Zanidatamab: this drug | Approved | Multispecific antibody | HER2 | Weak signal | NCT04466891: Confirmed ORR 41.3% (95% CI 30.4-52.8); median duration of response 12.9 months (Lancet Oncol 2023) | |
| Durvalumab | Approved | Monoclonal antibody | PD-L1 | not yet graded | No reviewed efficacy summary in this indication | |
| Pembrolizumab | Approved | Monoclonal antibody | PD-1 | Reliable signal | NCT04003636: Overall Survival (OS) (Up to approximately 38 months): Arm A: Pembrolizumab + Chemotherapy 12.7 Months (95% CI 11.5 to 13.6) | Arm B: Placebo + Chemotherapy 10.9 Months (95% CI 9.9 to 11.6) | |
| Futibatinib (Lytgobi) | Phase 3 | Small molecule | FGFR (FGFR1/2/3/4) | not yet graded | No reviewed efficacy summary in this indication | |
| Ivonescimab | Phase 3 | Multispecific antibody | PD-1 + VEGFA | not yet graded | No reviewed efficacy summary in this indication | |
| Izalontamab Brengitecan | Phase 3 | Antibody–drug conjugate | EGFR + HER3 | not yet graded | No reviewed efficacy summary in this indication | |
| Rilvegostomig | Phase 3 | Multispecific antibody | PD-1 and TIGIT | not yet graded | No reviewed efficacy summary in this indication | |
| Trastuzumab Brengitecan | Phase 3 | Antibody–drug conjugate | HER2 | not yet graded | No reviewed efficacy summary in this indication | |
| Tovecimig | Phase 2/3 | Multispecific antibody | DLL4 x VEGF-A | not yet graded | No reviewed efficacy summary in this indication | |
| Ramucirumab | Phase 2 | Monoclonal antibody | VEGFR2 | not yet graded | No reviewed efficacy summary in this indication | |
| RAD202 | Phase 1(overall) | Radiopharmaceutical | HER2 | not yet graded(overall) | No reviewed efficacy summary in this indication |
Upcoming events
(24 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow Zanidatamab to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2026 (2)
2027 (4)
June 2027 (1)
What to watch
December 2027 (3)
What to watch
What to watch
What to watch
2028 (12)
March 2028 (1)
What to watch
April 2028 (1)
What to watch
June 2028 (5)
What to watch
What to watch
What to watch
What to watch
What to watch
July 2028 (1)
What to watch
December 2028 (4)
What to watch
What to watch
What to watch
What to watch
2029 (3)
January 2029 (1)
What to watch
March 2029 (1)
What to watch
December 2029 (1)
What to watch
2030 (2)
2033 (1)
July 2033 (1)
What to watch
Regulatory and conference events
(8)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent